Low-dose aspirin for preventing recurrent venous thromboembolism
Field | Value | Language |
dc.contributor.author | Brighton, Timothy A | |
dc.contributor.author | Eikelboom, John W | |
dc.contributor.author | Gibbs, Harry | |
dc.contributor.author | Hague, Wendy | |
dc.contributor.author | Xavier, Denis | |
dc.contributor.author | Diaz, Rafael | |
dc.contributor.author | Kirby, Adrienne | |
dc.contributor.author | Simes, John | |
dc.date.accessioned | 2015-12-01 | |
dc.date.available | 2015-12-01 | |
dc.date.issued | 2012-11-22 | |
dc.identifier.citation | Brighton T, Eikelboom J, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J, ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine 2012; 367(21): 1979–1987. | en_AU |
dc.identifier.uri | http://hdl.handle.net/2123/14080 | |
dc.description.abstract | Patients who have had a first episode of unprovoked venous thromboembolism have a high risk of recurrence after anticoagulants are discontinued. Aspirin may be effective in preventing a recurrence of venous thromboembolism. Methods We randomly assigned 822 patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism to receive aspirin, at a dose of 100 mg daily, or placebo for up to 4 years. The primary outcome was a recurrence of venous thromboembolism. Results During a median follow-up period of 37.2 months, venous thromboembolism recurred in 73 of 411 patients assigned to placebo and in 57 of 411 assigned to aspirin (a rate of 6.5% per year vs. 4.8% per year; hazard ratio with aspirin, 0.74; 95% confidence interval [CI], 0.52 to 1.05; P = 0.09). Aspirin reduced the rate of the two prespecified secondary composite outcomes: the rate of venous thromboembolism, myocardial infarction, stroke, or cardiovascular death was reduced by 34% (a rate of 8.0% per year with placebo vs. 5.2% per year with aspirin; hazard ratio with aspirin, 0.66; 95% CI, 0.48 to 0.92; P = 0.01), and the rate of venous thromboembolism, myocardial infarction, stroke, major bleeding, or death from any cause was reduced by 33% (hazard ratio, 0.67; 95% CI, 0.49 to 0.91; P = 0.01). There was no significant between-group difference in the rates of major or clinically relevant nonmajor bleeding episodes (rate of 0.6% per year with placebo vs. 1.1% per year with aspirin, P = 0.22) or serious adverse events. Conclusions In this study, aspirin, as compared with placebo, did not significantly reduce the rate of recurrence of venous thromboembolism but resulted in a significant reduction in the rate of major vascular events, with improved net clinical benefit. These results substantiate earlier evidence of a therapeutic benefit of aspirin when it is given to patients after initial anticoagulant therapy for a first episode of unprovoked venous thromboembolism. (Funded by National Health and Medical Research Council [Australia] and others; Australian New Zealand Clinical Trials Registry number, ACTRN12605000004662.) | en_AU |
dc.description.sponsorship | Health Research Council (New Zealand), Australasian Society of Thrombosis and Hemostasis, National Heart Foundation of Australia, Bayer HealthCare, National Health and Medical Research Council (Australia) program grant 1037786 | en_AU |
dc.language.iso | en_US | en_AU |
dc.relation | NHMRC Program Grant 1037786, Health Research Council (New Zealand), Australasian Society of Thrombosis and Hemostasis, National Heart Foundation of Australia, Bayer HealthCare. | en_AU |
dc.subject | venous thrombosis | en_AU |
dc.subject | thromboembolism | en_AU |
dc.subject | aspirin | en_AU |
dc.subject | prevention | en_AU |
dc.title | Low-dose aspirin for preventing recurrent venous thromboembolism | en_AU |
dc.type | Article | en_AU |
dc.type.pubtype | Publisher's version | en_AU |
Associated file/s
Associated collections